Cellular Dynamics, Roche Update Alliance Covering Cardiotoxicity Platform | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that its agreement with Roche to substantiate CDI's platform for assessing the potential toxicity of drug candidates for heart disease has progressed to a standard supply agreement.

The two-year agreement, which took effect in March 2009, to substantiate CDI's iCell Cardiomyocytes as a predictive tool was completed early, and the platform will now be incorporated into Roche's drug development decision-making process, CDI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.